These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

296 related items for PubMed ID: 27569835

  • 1. Effects of pimobendan on myocardial perfusion and pulmonary transit time in dogs with myxomatous mitral valve disease: a pilot study.
    Apple SM, Menciotti G, Braz-Ruivo L, Crosara S, Häggström J, Borgarelli M.
    Aust Vet J; 2016 Sep; 94(9):324-8. PubMed ID: 27569835
    [Abstract] [Full Text] [Related]

  • 2. Short-term hemodynamic and neuroendocrine effects of pimobendan and benazapril in dogs with myxomatous mitral valve disease and congestive heart failure.
    Häggström J, Lord PF, Höglund K, Ljungvall I, Jöns O, Kvart C, Hansson K.
    J Vet Intern Med; 2013 Sep; 27(6):1452-62. PubMed ID: 24128373
    [Abstract] [Full Text] [Related]

  • 3. Longitudinal analysis of quality of life, clinical, radiographic, echocardiographic, and laboratory variables in dogs with myxomatous mitral valve disease receiving pimobendan or benazepril: the QUEST study.
    Häggström J, Boswood A, O'Grady M, Jöns O, Smith S, Swift S, Borgarelli M, Gavaghan B, Kresken JG, Patteson M, Åblad B, Bussadori CM, Glaus T, Kovačević A, Rapp M, Santilli RA, Tidholm A, Eriksson A, Belanger MC, Deinert M, Little CJ, Kvart C, French A, Rønn-Landbo M, Wess G, Eggertsdottir A, Lynne O'Sullivan M, Schneider M, Lombard CW, Dukes-McEwan J, Willis R, Louvet A, DiFruscia R.
    J Vet Intern Med; 2013 Sep; 27(6):1441-51. PubMed ID: 24010489
    [Abstract] [Full Text] [Related]

  • 4. Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Preclinical Myxomatous Mitral Valve Disease Receiving Pimobendan or Placebo: The EPIC Study.
    Boswood A, Gordon SG, Häggström J, Wess G, Stepien RL, Oyama MA, Keene BW, Bonagura J, MacDonald KA, Patteson M, Smith S, Fox PR, Sanderson K, Woolley R, Szatmári V, Menaut P, Church WM, O'Sullivan ML, Jaudon JP, Kresken JG, Rush J, Barrett KA, Rosenthal SL, Saunders AB, Ljungvall I, Deinert M, Bomassi E, Estrada AH, Fernandez Del Palacio MJ, Moise NS, Abbott JA, Fujii Y, Spier A, Luethy MW, Santilli RA, Uechi M, Tidholm A, Schummer C, Watson P.
    J Vet Intern Med; 2018 Jan; 32(1):72-85. PubMed ID: 29214723
    [Abstract] [Full Text] [Related]

  • 5. Impact of a combination of pimobendan, furosemide, and enalapril on heart rate variability in naturally occurring, symptomatic, myxomatous mitral valve degeneration dogs.
    Pirintr P, Saengklub N, Boonpala P, Hamlin RL, Kijtawornrat A.
    BMC Vet Res; 2023 Oct 12; 19(1):201. PubMed ID: 37821927
    [Abstract] [Full Text] [Related]

  • 6. Effect of pimobendan on the incidence of arrhythmias in small breed dogs with myxomatous mitral valve degeneration.
    Lake-Bakaar GA, Singh MK, Kass PH, Griffiths LG.
    J Vet Cardiol; 2015 Jun 12; 17(2):120-8. PubMed ID: 26007710
    [Abstract] [Full Text] [Related]

  • 7. Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study-A Randomized Clinical Trial.
    Boswood A, Häggström J, Gordon SG, Wess G, Stepien RL, Oyama MA, Keene BW, Bonagura J, MacDonald KA, Patteson M, Smith S, Fox PR, Sanderson K, Woolley R, Szatmári V, Menaut P, Church WM, O'Sullivan ML, Jaudon JP, Kresken JG, Rush J, Barrett KA, Rosenthal SL, Saunders AB, Ljungvall I, Deinert M, Bomassi E, Estrada AH, Fernandez Del Palacio MJ, Moise NS, Abbott JA, Fujii Y, Spier A, Luethy MW, Santilli RA, Uechi M, Tidholm A, Watson P.
    J Vet Intern Med; 2016 Nov 12; 30(6):1765-1779. PubMed ID: 27678080
    [Abstract] [Full Text] [Related]

  • 8. Effect of pimobendan on left atrial function in dogs with preclinical myxomatous mitral valve disease.
    Sarcinella F, Neves J, Maddox TW, Hodgkiss-Geere HM, Bode EF, Dukes-McEwan J.
    Open Vet J; 2020 Jan 12; 9(4):375-383. PubMed ID: 32042661
    [Abstract] [Full Text] [Related]

  • 9. Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study.
    Häggström J, Boswood A, O'Grady M, Jöns O, Smith S, Swift S, Borgarelli M, Gavaghan B, Kresken JG, Patteson M, Ablad B, Bussadori CM, Glaus T, Kovacević A, Rapp M, Santilli RA, Tidholm A, Eriksson A, Belanger MC, Deinert M, Little CJ, Kvart C, French A, Rønn-Landbo M, Wess G, Eggertsdottir AV, O'Sullivan ML, Schneider M, Lombard CW, Dukes-McEwan J, Willis R, Louvet A, DiFruscia R.
    J Vet Intern Med; 2008 Jan 12; 22(5):1124-35. PubMed ID: 18638016
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safet of pimobendan in canine heart failure caused by myxomatous mitral valve disease.
    Smith PJ, French AT, Van Israël N, Smith SG, Swift ST, Lee AJ, Corcoran BM, Dukes-McEwan J.
    J Small Anim Pract; 2005 Mar 12; 46(3):121-30. PubMed ID: 15789807
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of adding ramipril (VAsotop) to the combination of furosemide (Lasix) and pimobendan (VEtmedin) in dogs with mitral valve degeneration: The VALVE trial.
    Wess G, Kresken JG, Wendt R, Gaugele J, Killich M, Keller L, Simak J, Holler P, Bauer A, Küchenhof H, Glaus T.
    J Vet Intern Med; 2020 Nov 12; 34(6):2232-2241. PubMed ID: 32945575
    [Abstract] [Full Text] [Related]

  • 12. Symmetric dimethylarginine in dogs with myxomatous mitral valve disease at various stages of disease severity.
    Valente C, Guglielmini C, Domenech O, Contiero B, Zini E, Poser H.
    PLoS One; 2020 Nov 12; 15(9):e0238440. PubMed ID: 32870923
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics of pimobendan after oral administration to dogs with myxomatous mitral valve disease.
    McManamey AK, DeFrancesco TC, Meurs KM, Papich MG.
    J Vet Intern Med; 2023 Nov 12; 37(6):2003-2010. PubMed ID: 37776546
    [Abstract] [Full Text] [Related]

  • 14. Effect of atorvastatin on oxidative stress and inflammation markers in myxomatous mitral valve disease in dogs: A comparison of subclinical and clinical stages.
    Thassakorn P, Patchanee P, Pongkan W, Chattipakorn N, Boonyapakorn C.
    J Vet Pharmacol Ther; 2019 May 12; 42(3):258-267. PubMed ID: 30666669
    [Abstract] [Full Text] [Related]

  • 15. Utility of Tissue Doppler Imaging in the Echocardiographic Evaluation of Left and Right Ventricular Function in Dogs with Myxomatous Mitral Valve Disease with or without Pulmonary Hypertension.
    Baron Toaldo M, Poser H, Menciotti G, Battaia S, Contiero B, Cipone M, Diana A, Mazzotta E, Guglielmini C.
    J Vet Intern Med; 2016 May 12; 30(3):697-705. PubMed ID: 27177623
    [Abstract] [Full Text] [Related]

  • 16. Echocardiographic anatomy of the mitral valve in healthy dogs and dogs with myxomatous mitral valve disease.
    Wesselowski S, Borgarelli M, Menciotti G, Abbott J.
    J Vet Cardiol; 2015 Jun 12; 17(2):97-106. PubMed ID: 26003902
    [Abstract] [Full Text] [Related]

  • 17. Echocardiographic Estimates of Right Ventricular Systolic Function in Dogs with Myxomatous Mitral Valve Disease.
    Chapel EH, Scansen BA, Schober KE, Bonagura JD.
    J Vet Intern Med; 2018 Jan 12; 32(1):64-71. PubMed ID: 29224256
    [Abstract] [Full Text] [Related]

  • 18. Serum serotonin concentration is associated with severity of myxomatous mitral valve disease in dogs.
    Ljungvall I, Höglund K, Lilliehöök I, Oyama MA, Tidholm A, Tvedten H, Häggström J.
    J Vet Intern Med; 2013 Jan 12; 27(5):1105-12. PubMed ID: 23865457
    [Abstract] [Full Text] [Related]

  • 19. Noninvasive clinical assessment of systolic torsional motions by two-dimensional speckle-tracking echocardiography in dogs with myxomatous mitral valve disease.
    Suzuki R, Matsumoto H, Teshima T, Koyama H.
    J Vet Intern Med; 2013 Jan 12; 27(1):69-75. PubMed ID: 23278918
    [Abstract] [Full Text] [Related]

  • 20. Plasma and platelet serotonin concentrations in healthy dogs and dogs with myxomatous mitral valve disease.
    Mangklabruks T, Surachetpong SD.
    J Vet Cardiol; 2014 Sep 12; 16(3):155-62. PubMed ID: 25127665
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.